Otis W. Brawley bought Lyell Immunopharma ($LYEL) shares on the open market once in the last year, totaling nearly $20,000, with his most recent purchase on March 31, 2025. His activity ranks 3,850th among nearly 5,000 insiders, below the average purchase of $1.46 million across about 3.3 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 2158 | $111.75 | 12,985.6230 | 285,000,000 | 19.93% | 0.00% |
| March 19, 2026 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 888 | $111.75 | 13,873.6230 | 285,000,000 | 6.84% | 0.00% |
| Jan. 12, 2026 | PDS Biotechnology Corp | $PDSB | BRAWLEY OTIS W | Not found | A | Employee Stock Option (Right to Buy) | 54876 | $0.00 | 54,876.0000 | 48,980,307 | 9999.99% | 0.11% |
| June 10, 2025 | INCYTE CORP | $INCY | BRAWLEY OTIS W | Director | A | Non Qualfied Stock Option (right to buy) | 9216 | $0.00 | 9,216.0000 | 210,530,000 | 9999.99% | 0.00% |
| June 10, 2025 | INCYTE CORP | $INCY | BRAWLEY OTIS W | Director | A | Common Stock | 2518 | $0.00 | 11,252.0000 | 210,530,000 | 28.83% | 0.00% |
| June 11, 2025 | PDS Biotechnology Corp | $PDSB | BRAWLEY OTIS W | Not found | A | Employee Stock Option (Right to Buy) | 22700 | $0.00 | 22,700.0000 | 45,395,851 | 9999.99% | 0.05% |
| May 15, 2025 | Lyell Immunopharma, Inc. | $LYEL | BRAWLEY OTIS W | Not found | A | Option (right to buy) | 130000 | $0.00 | 130,000.0000 | 295,228,868 | 9999.99% | 0.04% |
| March 31, 2025 | Lyell Immunopharma, Inc. | $LYEL | BRAWLEY OTIS W | Not found | P | Common Stock | 35640 | $0.56 | 35,640.0000 | 295,228,868 | 9999.99% | 0.01% |
| March 14, 2025 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 1819 | $121.18 | 9,929.9300 | 291,000,000 | 22.43% | 0.00% |
| March 14, 2025 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 812 | $121.18 | 10,741.9300 | 291,000,000 | 8.18% | 0.00% |
| June 24, 2024 | PDS Biotechnology Corp | $PDSB | BRAWLEY OTIS W | Not found | A | Employee Stock Option (Right to Buy) | 9000 | $0.00 | 9,000.0000 | 0 | 9999.99% | 0.00% |
| June 14, 2024 | Lyell Immunopharma, Inc. | $LYEL | BRAWLEY OTIS W | Not found | A | Option (right to buy) | 130000 | $0.00 | 130,000.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | INCYTE CORP | $INCY | BRAWLEY OTIS W | Director | A | Non Qualfied Stock Option (right to buy) | 12517 | $0.00 | 12,517.0000 | 225,928,000 | 9999.99% | 0.01% |
| June 12, 2024 | INCYTE CORP | $INCY | BRAWLEY OTIS W | Director | A | Common Stock | 2830 | $0.00 | 8,734.0000 | 225,928,000 | 47.93% | 0.00% |
| March 15, 2024 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 1678 | $147.48 | 7,305.4570 | 296,000,000 | 29.82% | 0.00% |
| March 15, 2024 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 750 | $147.48 | 8,055.4570 | 296,000,000 | 10.27% | 0.00% |
| Sept. 8, 2023 | Lyell Immunopharma, Inc. | $LYEL | BRAWLEY OTIS W | Director | A | Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| July 14, 2023 | PDS Biotechnology Corp | $PDSB | BRAWLEY OTIS W | Not found | A | Employee Stock Option (Right to Buy) | 9000 | $0.00 | 9,000.0000 | 0 | 9999.99% | 0.00% |
| June 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | BRAWLEY OTIS W | Director | A | Option (right to buy) | 65000 | $0.00 | 65,000.0000 | 0 | 9999.99% | 0.00% |
| March 16, 2023 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 1658 | $136.82 | 4,844.2760 | 0 | 52.04% | 0.00% |
| March 16, 2023 | AGILENT TECHNOLOGIES, INC. | $A | BRAWLEY OTIS W | Director | A | Common Stock | 741 | $136.82 | 5,585.2760 | 0 | 15.30% | 0.00% |